Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cerus and Grifols have entered into an agreement to extend Grifols’ Intercept platelet and plasma distribution to Italy. The Intercept blood system inactivates a broad range of viruses, bacteria and parasites that may contaminate donated blood components, including emerging pathogens such as west nile virus, chikungunya and influenza virus.
Subscribe to our email newsletter
Claes Glassell, President and CEO of Cerus, said: “we are pleased to broaden and further strengthen our relationship with Grifols, one of the largest pharmaceutical companies in Spain and the largest European plasma fractionator.”
“Building on our success to date, we look forward to working with Grifols in Italy to increase adoption of Intercept platelets and plasma,” he added.
Riccardo Vanni, Managing Director of Grifols Italia, said: “the Intercept technology perfectly complements Grifols’ transfusion line of products in Italy and is a good fit in terms of our marketing and sales organization.”